Myomo (MYO) Q2 2025: Pipeline Adds Jump 49% as Channel Shift, Cost Cuts Target Conversion Headwinds

2025-08-11 | By EarningsIQ Research

Myomo’s Q2 saw record lead generation and a 49% jump in pipeline adds, but higher costs and conversion friction forced a strategic pivot in channel mix and spending discipline. The company is redirecting advertising from social media to television and deepening clinical referral programs to offset lower lead quality and ongoing Medicare Advantage denials. Full-year guidance was revised, with execution now hinging on improved conversion rates and cost control as Myomo leans into diversified sourcing and international growth.

Summary

• Lead Quality Challenge: Record leads failed to translate into proportional pipeline growth, spotlighting a need for channel recalibration.
• Cost and Conversion Pressure: Cost per pipeline add nearly doubled amid lower Facebook lead quality and persistent Medicare Advantage denials.
• Strategic Channel Shift: Myomo is reallocating spend to TV and clinical referrals, aiming for more efficient patient acquisition and revenue conversion.

Performance Analysis

Q2 revenue rose 28% year-over-year, driven by a 13% increase in MyoPro revenue units and a 14% higher average selling price. Medicare Part B patients accounted for 56% of revenue, reflecting the ongoing impact of expanded coverage. International revenue, primarily from Germany, climbed 41% and now represents 15% of the total, highlighting geographic diversification.

Despite these gains, cost per pipeline add surged to nearly $2,900, up 89% year-over-year, as Facebook leads underperformed and conversion rates from lead to pipeline add declined. Gross margin fell to 62.7% from 70.8% in the prior quarter, pressured by increased material costs, demo unit builds, and overhead. Operating expenses jumped 65% due to heavier advertising spend and expanded headcount, resulting in a widened operating loss of $4.6 million.

• Pipeline Growth Outpaces Backlog: Pipeline reached 1,611 patients (+37% YoY), but backlog declined 19% as conversion rates lagged.
• Direct Billing Dominates: The direct billing channel contributed 77% of revenue, though its growth is increasingly dependent on channel optimization and payer mix.
• International Strength: Germany’s model, with over 100 certified provider locations, is being replicated in the US to drive referral-based growth.

Cash burn normalized to $4.9 million after excluding temporary drivers, with $15.5 million in cash and equivalents providing a 12-month runway. Full-year revenue guidance was set at 23–29% growth, contingent on improved conversion rates and continued cost discipline.

Executive Commentary

Strategic Positioning

1. Channel Mix Recalibration

Myomo is shifting advertising dollars from social media to television, responding to a sharp decline in Facebook lead quality after privacy policy changes. TV leads show higher engagement and better conversion to pipeline adds, albeit at a higher cost per lead but potentially lower cost per pipeline add. This tactical move is designed to restore efficiency in patient acquisition and reduce dependence on volatile digital ad platforms.

2. Clinical Referral Expansion

The company is doubling down on clinical referral programs, training over 1,500 occupational therapists and organizing “screening days” at rehab facilities. This approach aims to source higher-quality, incident population patients (those recently affected by stroke) earlier in their care journey, increasing the likelihood of successful MyoPro adoption and reimbursement.

3. Payer Strategy and Appeals

Medicare Advantage denials remain a structural headwind, with only about 15% first-time authorization rates. Myomo is escalating appeals, including more cases to administrative law judge hearings, and actively engaging with payers and regulators to enforce compliance with Medicare policy. Commercial plan contracting is also expanding, with 35 million lives now covered by signed or pending agreements.

4. International Model Replication

Germany’s success—driven by a network of certified providers and active clinical engagement—is informing US strategy. Myomo is scaling up provider certification and clinical outreach, targeting both direct and O&P (orthotics and prosthetics) channels to diversify sourcing and reduce reliance on advertising.

5. Cost Discipline and Focused Investment

Headcount was reduced by 8% in July, with further hiring freezes outside critical clinical roles. Operating expense controls and capital allocation are tightly linked to revenue growth and channel productivity, aiming for sustainable cash flow positive operations.

Key Considerations

This quarter marks a pivotal recalibration of Myomo’s growth engine, as management responds to digital channel volatility, payer friction, and rising costs with a multi-pronged strategy targeting channel mix, referral sourcing, and disciplined spending.

Key Considerations:

• Lead Quality Volatility: Facebook privacy changes sharply reduced lead quality, forcing a pivot to higher-cost but more effective TV advertising and referral channels.
• Conversion Rate Pressure: Pipeline-to-authorization conversion rates declined, especially for Medicare Advantage, constraining backlog growth and revenue visibility.
• Cost Structure Flexibility: Operating expense cuts and hiring discipline are intended to protect cash runway and align spending with revenue opportunities.
• International Playbook: Germany’s provider-centric model is being adapted for the US, with early signs of O&P channel growth but still low absolute volumes.

Risks

Persistent conversion headwinds, especially with Medicare Advantage denials and increasing patient disqualification rates, threaten revenue growth and backlog replenishment. Lead quality uncertainty, ongoing reimbursement friction, and potential cost inflation (including tariffs) add further risk to margin stability and cash flow timelines. Management’s ability to execute on channel and referral pivots will be critical to offset these pressures.

Forward Outlook

For Q3 2025, Myomo guided to:

• Revenue of $9.5–10 million, up 3–9% year-over-year

For full-year 2025, management raised guidance to:

• Revenue of $40–42 million, up 23–29% versus 2024

Management highlighted that guidance assumes stable conversion rates, improved Medicare Part B patient flow, and continued cost discipline.

• Advertising spend will remain flat in Q3, with a seasonal decline in Q4
• Cost per pipeline add expected to decrease in Q3 as TV and referral channels ramp

Takeaways

Myomo’s Q2 underscores the challenge of scaling a high-touch medical device business amid digital channel disruption and payer complexity.

• Pipeline and Backlog Divergence: Pipeline growth outpaced backlog as conversion and authorization rates lagged, highlighting the need for improved lead quality and channel diversification.
• Cost Control Imperative: Operating expense reductions and hiring freezes are a necessary response to margin compression and higher acquisition costs.
• Execution Watchpoint: Investors should monitor the effectiveness of TV and referral channels in driving qualified pipeline adds and the pace of O&P channel scaling, as well as any further shifts in payer mix or reimbursement policy.

Conclusion

Myomo’s Q2 marked a decisive pivot toward more sustainable, diversified growth levers, with execution risk now centered on the ability to translate channel and referral investments into improved conversion and margin recovery. Near-term results will hinge on cost discipline and payer engagement, while international and O&P channel expansion offer longer-term optionality.

Industry Read-Through

Myomo’s experience spotlights the volatility of digital lead generation in regulated health markets, as privacy-driven platform changes can materially disrupt acquisition economics. Medical device companies reliant on direct-to-patient channels face rising conversion costs and must invest in clinical referral networks and provider partnerships to stabilize pipeline quality. Payer friction, especially from Medicare Advantage, is a growing structural challenge across the sector, requiring robust appeals infrastructure and contracting strategies. International provider-centric models may offer a blueprint for US market adaptation, but require significant clinical engagement and certification investment.

MYO Healthcare Medical Devices Patient Acquisition Reimbursement Channel Strategy Cost Management